Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Inoperable œsophageal Cancer × Ipilimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 106 Carcinoma, Non-Small-Cell Lung 33 Carcinoma, Renal Cell 23 Prostatic Neoplasms 17 Neoplasms 15 Brain Neoplasms 15 Neoplasm Metastasis 14 Lung Neoplasms 11 Breast Neoplasms 11 Uveal Melanoma 10 Pancreatic Neoplasms 10 Sarcoma 9 Small Cell Lung Carcinoma 7 Urinary Bladder Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 6 Kidney Neoplasms 6 Diabetes Mellitus, Insulin-Dependent, 12 6 Carcinoma, Transitional Cell 6 Carcinoma, Hepatocellular 6 Skin Neoplasms 5 Ovarian Neoplasms 5 Histiocytoma, Malignant Fibrous 5 Colorectal Neoplasms 5 Uterine Cervical Neoplasms 4 Triple Negative Breast Neoplasms 4 Recurrence 4 Neuroendocrine Tumors 4 Mesothelioma 4 Glioblastoma 4 Colonic Neoplasms 4

Interventions

Nivolumab 1 Ipilimumab 1 Chemoradiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03437200 2023-02-21

CRUCIAL

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Terminated

Inoperable œsophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡